OVERVIEW

AICAR 50 mg refers to a synthetic compound (5-aminoimidazole-4-carboxamide ribonucleotide) often used in research settings to activate the enzyme AMP-activated protein kinase (AMPK), a key regulator of cellular energy balance. By mimicking a low-energy state, AICAR can stimulate pathways that increase glucose uptake and fatty acid oxidation in muscle cells, which has made it of interest in studies on endurance, metabolism, and muscle physiology. In laboratory models, AICAR has shown the ability to enhance endurance and improve metabolic profiles by shifting cells toward greater energy efficiency. A 50 mg dose is a relatively modest amount typical of research protocols, though dosing can vary depending on experimental design and species.

Despite research interest, AICAR is not approved by major regulatory agencies such as the U.S. Food and Drug Administration for therapeutic use in humans. There is limited clinical evidence supporting its efficacy or safety outside of controlled laboratory studies. In the context of sports, AICAR has been listed by anti-doping authorities as a prohibited substance due to its potential performance-enhancing effects, and its use can carry legal and ethical risks for athletes. Because of the lack of approved medical indications and safety data, individuals should not self-administer AICAR; anyone curious about metabolic or exercise-related interventions should consult qualified healthcare professionals for evidence-based strategies.